Hydrocodone Polistirex

CHEMBL1201470 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
299.4 g/mol
LogP
2.2
Phase
4

A polymer-bound form of hydrocodone that creates an extended-release formulation by slowing the release of the active opioid in the gastrointestinal tract, providing longer-lasting cough suppression than immediate-release hydrocodone preparations. This formulation is designed for twice-daily dosing in the management of cough. As with all opioid formulations, risks of dependence and respiratory depression require careful patient monitoring.

Peso Molecular

299,4000 g/mol

LogP

2,20

TPSA

38,80 Ų

Regra dos 5 de Lipinski

Aprovado

Mecanismo de Ação

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4

InChI

InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1

Molecular Formula

C18H21NO3

HBD / HBA

- / 4

Ligações Rotacionáveis

1

Átomos Pesados

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A polymer-bound form of hydrocodone that creates an extended-release formulation by slowing the release of the active opioid in the gastrointestinal tract, providing longer-lasting cough suppression than immediate-release hydrocodone preparations. This formulation is designed for twice-daily dosing in the management of cough. As with all opioid formulations, risks of dependence and respiratory depression require careful patient monitoring.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Hydrocodone Polistirex is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201470. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5284569. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.